Table 4.
Changes in patients’ serum cholesterol profiles during the trial, and comparison between groups.
| Variables |
Control Group | Experimental Group | Between Groups | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T0 | T1 | T2 | Difference | T0 | T1 | T2 | Difference | T0 | T1 | T2 | Difference | ||||||||
| T0–T1 | T0–T2 | T0–T1 | T0–T2 | T0–T1 | T0–T2 | ||||||||||||||
| Median (25th–75th) Percentile |
P a | Median (25th–75th) Percentile |
P b | Median (25th–75th) Percentile |
P a | Median (25th–75th) Percentile |
P b | P c | P c | P c | P c | P c | |||||||
| TCL (mg/dL) |
142.2 (130.9–162.8) |
129.5 (112.6–148.0) |
142.7 (135.0–175.9) |
0.179 | 10.9 (−1.5–47.9) |
−7.8 (−22.7–13.1) |
0.058 | 158.1 (141.1–214.0) |
131.4 (117.4–170.1) |
149.6 (124.3–158.4) |
0.001 | 25.0 (14.4–30.5) |
31.1 (−2.0–65.6) |
0.679 | 0.056 | 0.438 | 0.937 | 0.261 | 0.018 |
| CL LDL (mg/dL) |
71.8 (60.7–90.1) |
66.2 (51.1–83.1) |
82.0 (69.8–87.3) |
0.029 | 9.1 (−6.3–29.11) |
−8.77 (−18.2–0.7) |
0.053 | 83.7 (73.1–128.4) |
62.9 (59.6–102.3) |
73.4 (68.8–90.6) |
0.003 | 14.1 (8.1–26.8) |
6.6 (0.42–49.1) |
0.586 | 0.074 | 0.420 | 0.579 | 0.248 | 0.005 |
| CL HDL (mg/dL) |
44.2 (39.8–49.3) |
41.2 (35.6–47.7) |
44.8 (36.9–53.2) |
0.029 | 2.9 (−1.5–6.4) |
−2.6 (−7.7–2.6) |
0.014 | 43.0 (35.1–51.6) |
38.3 (32.3–44.0) |
42.2 (36.1–53.1) |
0.017 | 3.2 (0.0–7.3) |
−2.1 (−5.5–2.9) |
0.043 | 0.987 | 0.351 | 0.635 | 0.517 | 0.537 |
| AI (rel. un.) |
2.58 (1.91–3.11) |
2.18 (1.75–2.44) |
2.44 (1.79–3.08) |
0.066 | 0.31 (−0.21–0.75) |
0.12 (−0.48–0.58) |
0.078 | 3.13 (2.53–4.09) |
2.59 (1.81–3.42) |
2.39 (1.79–2.71) |
0.030 | 0.44 (−0.02–0.86) |
0.62 (0.11–1.53) |
0.306 | 0.074 | 0.079 | 0.812 | 0.517 | 0.064 |
a—based on a Freidman ANOVA, b—based on a two-tailed Wilcoxon test, c—based on a two-tailed Mann–Whitney U test.